ABSTRACT
INTRODUCTION: The rate of bacterial coinfection with SARS-CoV-2 is poorly defined. The decision to administer antibiotics early in the course of SARS-CoV-2 infection depends on the likelihood of bacterial coinfection. METHODS: We performed a retrospective chart review of all patients admitted through the emergency department with confirmed SARS-CoV-2 infection over a 6-week period in a large healthcare system in the United States. Blood and respiratory culture results were abstracted and adjudicated by multiple authors. The primary outcome was the rate of bacteremia. We secondarily looked to define clinical or laboratory features associated with bacteremia. RESULTS: There were 542 patients admitted with confirmed SARS-CoV-2 infection, with an average age of 62.8 years. Of these, 395 had blood cultures performed upon admission, with six true positive results (1.1% of the total population). An additional 14 patients had positive respiratory cultures treated as true pathogens in the first 72 h. Low blood pressure and elevated white blood cell count, neutrophil count, blood urea nitrogen, and lactate were statistically significantly associated with bacteremia. Clinical outcomes were not statistically significantly different between patients with and without bacteremia. CONCLUSIONS: We found a low rate of bacteremia in patients admitted with confirmed SARS-CoV-2 infection. In hemodynamically stable patients, routine antibiotics may not be warranted in this population.
Subject(s)
Bacterial Infections/epidemiology , COVID-19/epidemiology , Coinfection/epidemiology , Emergency Service, Hospital/statistics & numerical data , Anti-Bacterial Agents/therapeutic use , Bacteremia/diagnosis , Bacteremia/epidemiology , Bacteremia/therapy , Bacterial Infections/diagnosis , Bacterial Infections/therapy , COVID-19/diagnosis , COVID-19/therapy , Coinfection/diagnosis , Coinfection/therapy , Female , Hospitalization , Hospitals , Humans , Indiana/epidemiology , Male , Middle Aged , Retrospective Studies , Risk Factors , SARS-CoV-2/isolation & purification , Treatment OutcomeABSTRACT
Fusobacterium nucleatum is a periodontal commensal and pathogen. In rare cases, these anaerobic gram-negative bacilli have been reported to cause pyogenic liver abscesses (PLAs). We describe a patient who developed a periodontal abscess during the COVID-19 pandemic and was unable to access the restricted General Dental Services at this time. She subsequently developed a F. nucleatum bacteraemia and liver abscess. The non-specific signs and symptoms experienced meant the patient self-isolated due to suspected COVID-19 infection and presentation to hospital was delayed. We also include the results of a literature search of other cases of PLAs attributed to F. nucleatum PLAs often develop insidiously. They require percutaneous drainage and prolonged antimicrobial therapy. Clinicians should be aware of this rare complication of a dentoalveolar infection in a patient who is systemically unwell.
Subject(s)
Fusobacterium Infections/diagnosis , Liver Abscess, Pyogenic/microbiology , Periodontal Abscess/microbiology , Anti-Bacterial Agents/therapeutic use , Bacteremia/diagnosis , COVID-19/epidemiology , Drainage , Female , Fusobacterium Infections/diagnostic imaging , Fusobacterium Infections/drug therapy , Humans , Liver Abscess, Pyogenic/diagnostic imaging , Liver Abscess, Pyogenic/drug therapy , Middle Aged , Pandemics , Quarantine , SARS-CoV-2 , Time-to-Treatment , Tomography, X-Ray ComputedABSTRACT
OBJECTIVES: Coronavirus disease (COVID-19) blindness, that is, the excessive consideration of the disease in diagnosis, has reportedly led to delayed diagnosis of some diseases. We compared several clinical measures between patients admitted for bacteremia during the two months of the COVID-19 pandemic and those admitted during the same period in 2019. We hypothesized that the pandemic has led to delayed treatment of bacteremia. METHODS: This retrospective observational study compared several measures undertaken for patients who visited the emergency unit in two hospitals between March 1 and May 31, 2020, during the COVID-19 pandemic and whose blood cultures tested positive for bacteremia with those for corresponding patients treated during the same period in 2019. The primary measure was time from consultation to blood culture/antimicrobials. RESULTS: We included 29 eligible patients from 2020 and 26 from 2019. In 2020, the time from consultation to antimicrobial administration was significantly longer than in 2019 (mean [range], 222 [145-309] min vs. 139 [102-179] min, p=0.002). The frequency of chest computed tomography (CT) was significantly higher in 2020 (96.6 vs. 73.1%, p=0.021). Significant differences were not observed in the time to blood culture or chest CT preceding the blood culture between the two periods. CONCLUSIONS: Our findings suggested that due to the COVID-19 epidemic/pandemic, focusing on the exclusion of its infection using CT scans leads to an overall delay in the diagnosis and treatment of bacteremia. Medical providers must be aware of COVID-19 blindness and evaluate patients objectively based on rational criteria and take appropriate action.
Subject(s)
Bacteremia/drug therapy , Bacteremia/epidemiology , COVID-19/epidemiology , Pandemics , Time-to-Treatment/statistics & numerical data , Aged , Aged, 80 and over , Bacteremia/diagnosis , Female , Humans , Male , Retrospective Studies , SARS-CoV-2ABSTRACT
We observed bacterial or fungal coinfections in COVID-19 patients admitted between March 1 and April 18, 2020 (152 of 4,267, 3.6%). Among these patients, mortality was 57%; 74% were intubated; 51% with bacteremia had central venous catheters. Time to culture positivity was 6-7 days, and 79% had received prior antibiotics. Metallo-ß-lactamase-producing E. cloacae coinfections occurred in 5 patients.
Subject(s)
Anti-Bacterial Agents/therapeutic use , Bacteremia , COVID-19 , Coinfection , Mycoses , SARS-CoV-2/isolation & purification , Bacteremia/diagnosis , Bacteremia/epidemiology , Bacteremia/therapy , COVID-19/epidemiology , COVID-19/microbiology , COVID-19/therapy , Central Venous Catheters/microbiology , Central Venous Catheters/statistics & numerical data , Coinfection/epidemiology , Coinfection/microbiology , Coinfection/virology , Drug Resistance, Bacterial , Female , Humans , Male , Microbiological Techniques/methods , Microbiological Techniques/statistics & numerical data , Middle Aged , Mycoses/diagnosis , Mycoses/epidemiology , Mycoses/therapy , New York/epidemiology , Outcome and Process Assessment, Health Care , Respiration, Artificial/statistics & numerical data , Severity of Illness IndexABSTRACT
Rapid response services provide opportunities for older people living with frailty to remain in their own homes during an episode of deteriorating health. The government has announced additional funding to increase capacity and responsiveness for these services through the Ageing Well programme as part of the NHS Long Term Plan. Older people living with frailty are particularly at risk of the adverse effects of a hospital admission and evidence is emerging of the benefits of enhanced healthcare support to allow them to remain in their own home. The Hospital at Home model offers short-term, targeted interventions at acute hospital level care that can provide a truly person-centred experience within the home. This article describes a Rapid Response and Treatment service for older people living in care homes in Berkshire West and shares Sid's story to demonstrate how such a service is delivered. The COVID-19 pandemic has presented additional challenges and opportunities that highlight the ongoing need for the development of services that will support older people to prioritise what matters to them most.